Profit Margin (Quarterly) Chart

View Profit Margin (Quarterly) for PFE.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Profit Margin (Quarterly) Chart
Start Trial

Historical Profit Margin (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 -1.64%
March 31, 2026 18.75%
December 31, 2025 -9.34%
September 30, 2025 21.32%
June 30, 2025 19.81%
March 31, 2025 21.68%
December 31, 2024 2.31%
September 30, 2024 25.31%
June 30, 2024 0.23%
March 31, 2024 21.02%
December 31, 2023 -22.89%
September 30, 2023 -17.70%
June 30, 2023 17.99%
March 31, 2023 30.05%
December 31, 2022 20.59%
September 30, 2022 38.19%
June 30, 2022 35.60%
March 31, 2022 30.70%
December 31, 2021 15.01%
September 30, 2021 34.00%
June 30, 2021 30.82%
March 31, 2021 33.65%
December 31, 2020 5.45%
September 30, 2020 8.92%
June 30, 2020 26.40%
Date Value
March 31, 2020 24.63%
December 31, 2019 -2.58%
September 30, 2019 60.57%
June 30, 2019 38.12%
March 31, 2019 29.65%
December 31, 2018 -2.74%
September 30, 2018 30.91%
June 30, 2018 28.81%
March 31, 2018 27.66%
December 31, 2017 89.67%
September 30, 2017 21.70%
June 30, 2017 23.86%
March 31, 2017 24.49%
December 31, 2016 5.60%
September 30, 2016 10.39%
June 30, 2016 15.68%
March 31, 2016 23.44%
December 31, 2015 -1.18%
September 30, 2015 17.62%
June 30, 2015 22.23%
March 31, 2015 21.87%
December 31, 2014 9.58%
September 30, 2014 21.65%
June 30, 2014 22.87%
March 31, 2014 19.95%

Profit Margin Definition

Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.

Read full definition.

Profit Margin (Quarterly) Range, Past 5 Years

View Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Profit Margin (Quarterly) Benchmarks

View Profit Margin (Quarterly) Benchmarks
Start Trial
Johnson & Johnson 21.86%
Eli Lilly & Co. 30.88%
Merck & Co., Inc. -8.06%
Bristol Myers Squibb Co. 25.54%
Viatris, Inc. -3.16%